Trademark Overview
On Monday, December 8, 2025, a trademark application was filed for NEWCELX with the United States Patent and Trademark Office. The USPTO has given the NEWCELX trademark a serial number of 79444171. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, February 19, 2026. This trademark is owned by KADIMASTEM LTD.. The NEWCELX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Research and development services in the field of biotechnology; research and development services in the field of pharmaceutical preparations; research and development services in the field of stem cells; research and development services in the field of cell therapy; research and development of induced pluripotent stem cells; research and development services in the field of pharmaceutical preparations, namely research and development of proprietary cell lines for the treatment of diabetes and ALS; research and development services in the field of pharmaceutical preparations, namely research and development of pluripotent stem cells for the treatment of neurodegenerative and metabolic diseases; scientific research in the medical and pharmaceutical field, and consultancy and information relating thereto; design and development of technology for cell therapy for the treatment of degenerative diseases; pharmaceutical drug development services; development of products for others in the f...
Pharmaceutical preparations for the treatment of degenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of metabolic disorders; pharmaceutical preparations, namely cell therapy for the treatment of diabetes and ALS; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of ALS; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of narcolepsy; stem cells for medical purposes; pharmaceutical compositions containing stem cells; pharmaceutical compositions containing stem cells for the treatment of degenerative diseases; pharmaceutical compositions containing stem cells for the treatment of neurodegenerative and metabolic diseases.
